Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers.

La Verde N, Collovà E, Lonardi S, Generali D, Moretti A, Atzori F, Cazzaniga M, Saggia C, Tondulli L, Marcon I, Gentile AL, Rossello R, Martelli O, Aglione S, Farina G, Cinquini M, Garassino M.

Tumori. 2013 Sep-Oct;99(5):596-600. doi: 10.1700/1377.15308.

PMID:
24362863
2.

Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.

Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Oncol Rep. 2010 May;23(5):1213-20.

PMID:
20372832
3.

Male breast cancer: a survey at the Helsinki University Central Hospital during 1981-2006.

Liukkonen S, Saarto T, Mäenpää H, Sjöström-Mattson J.

Acta Oncol. 2010 Apr;49(3):322-7. doi: 10.3109/02841861003591723.

PMID:
20397767
4.

Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.

Vargo JA, Beriwal S, Ahrendt GM, Soran A, Johnson RR, McGuire K, Bhargava R.

Oncology. 2011;80(5-6):341-9. doi: 10.1159/000330203. Epub 2011 Jul 26.

PMID:
21791944
5.

Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.

Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Tumori. 2010 Jan-Feb;96(1):103-10.

6.

The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.

Das U, Lakshmaiah KC, Govind Babu K, Suresh TM, Lokanatha D, Jacob L, Babu S.

J Cancer Res Clin Oncol. 2014 Oct;140(10):1777-82. doi: 10.1007/s00432-014-1724-1. Epub 2014 Jun 4.

PMID:
24894013
7.

[Prevalence of male breast cancer in our department during a 5-year period].

Cseh I, Kerekes M, Solymosi T.

Magy Seb. 2011 Jun;64(3):112-5. doi: 10.1556/MaSeb.64.2011.3.2. Hungarian.

PMID:
21672681
8.

Poorer survival of male breast cancer compared with female breast cancer patients may be due to biological differences.

Chen X, Liu X, Zhang L, Li S, Shi Y, Tong Z.

Jpn J Clin Oncol. 2013 Oct;43(10):954-63. doi: 10.1093/jjco/hyt116. Epub 2013 Aug 9.

PMID:
23935206
9.

Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J; Danish Breast Cancer Cooperative Group..

J Clin Oncol. 2008 Mar 20;26(9):1419-26. doi: 10.1200/JCO.2007.14.5565. Epub 2008 Feb 19.

PMID:
18285604
10.

Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.

Cortesi L, De Matteis E, Cirilli C, Marcheselli L, Proietto M, Federico M.

Tumori. 2012 Nov;98(6):743-50. doi: 10.1700/1217.13498.

PMID:
23389361
11.

Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.

Jeong JH, Jung SY, Park IH, Lee KS, Kang HS, Kim SW, Kwon Y, Kim EA, Ko KL, Nam BH, Lee S, Ro J.

Invest New Drugs. 2012 Feb;30(1):408-16. doi: 10.1007/s10637-010-9555-7. Epub 2010 Oct 5.

PMID:
20922557
12.

c-erbB-2 and the "triple-state" in early breast carcinomas.

Sivridis E, Stamos C, Fiska A, Nikolettos N, Koukourakis MI, Giatromanolaki A.

Med Oncol. 2010 Sep;27(3):578-84. doi: 10.1007/s12032-009-9252-6. Epub 2009 Jun 23.

PMID:
19548127
13.

Breast cancer in very young women.

Liukkonen S, Leidenius M, Saarto T, Sjöström-Mattson J.

Eur J Surg Oncol. 2011 Dec;37(12):1030-7. doi: 10.1016/j.ejso.2011.08.133. Epub 2011 Sep 21.

PMID:
21937191
14.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

15.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696
16.

Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors.

Chen X, Yu X, Chen J, Zhang Z, Tuan J, Shao Z, Guo X, Feng Y.

Cancer. 2013 Jul 1;119(13):2366-74. doi: 10.1002/cncr.28085. Epub 2013 Apr 10.

17.

Clinical features of male breast cancer and multimodal treatment: a comment to retrospective survey analysis at Italian centers.

D'Onofrio L, Tonini G, Santini D.

Tumori. 2014 Jul-Aug;100(4):169e-70e. doi: 10.1700/1636.17944. No abstract available.

PMID:
25296612
18.

The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.

Gabos Z, Thoms J, Ghosh S, Hanson J, Deschênes J, Sabri S, Abdulkarim B.

Breast Cancer Res Treat. 2010 Nov;124(1):187-94. doi: 10.1007/s10549-010-1135-1. Epub 2010 Sep 3.

PMID:
20814819
19.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.

PMID:
16145046
20.

[Current status of treatment for early-stage invasive breast cancer].

Kásler M, Polgár C, Fodor J.

Orv Hetil. 2009 May 31;150(22):1013-21. doi: 10.1556/OH.2009.28615. Hungarian.

PMID:
19465349

Supplemental Content

Support Center